SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Inside the alleged Russian operation to trigger anti-government protests in Angola - 2US FDA declines to approve Corcept's drug for rare hormonal disorder
- 3Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs
- 4Monetary Wellness: Planning Tips for Independence from the rat race
- 519 Strange Motion pictures You Shouldn't Watch With Your Mum
- Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Want to make America healthy again? Stop fueling climate change
- Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- Norovirus is spreading earlier again this year, wastewater data shows
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Vote In favor of Your Favored Shimmering Water
